VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
APLSApellis Pharmaceuticals, Inc.
$41.03$5.3B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAPLSP/E History

APLS logoApellis Pharmaceuticals, Inc. (APLS) P/E Ratio History

Expensive

Trading at 227.9x vs 5Y avg 85.5x · 100th percentile · Material premium to history · Data 2025–2026

Current P/E (TTM)
227.9x
+166% vs 5Y avg
5Y Avg P/E
85.5x
Median 64.7x
5Y Percentile
100th
Upper end of range
PEG Ratio
N/A
5-Year P/E Range
227.9x
Min44.2xMedian64.7xMax147.8x
TTM EPSN/A
Price$41.03
Earnings Yield0.44%
EPS Growth (1Y)111.3%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

The current P/E is 166% above its 5-year average of 85.5x. Over the past five years, APLS's P/E has ranged from a low of 44.2x to a high of 147.8x, placing the current valuation at the 100th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, APLS trades at a 930% premium to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.

Relative to the broader market, APLS commands a significant premium over the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our APLS DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

APLS Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
227.9vs22.1
+930%
Above Sector
vs. S&P 500
227.9vs24.3
+837%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 111% EPS growth (1Y)

APLS P/E vs Peers

Immunology and Inflammation Therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$2B6.9Lowest0.66+817%Best
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$64B14.82.32+8%
BIIB logoBIIBBiogen Inc.
$29B22.6--21%
OMAB logoOMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V.
$5B17.20.47Best+8%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

APLS Historical P/E Data (2025–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$40.23$0.9144.2x-48%
FY2025 Q4Dec 31 2025$25.12$0.17147.8x+73%
FY2025 Q3-$22.63$0.3564.7x-24%

Average P/E for displayed period: 85.5x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

1+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

APLS — Frequently Asked Questions

Quick answers to the most common questions about buying APLS stock.

What is APLS's P/E ratio?

Apellis Pharmaceuticals, Inc. (APLS) trailing twelve-month P/E ratio is 227.9x, based on TTM diluted EPS of N/A. The 5-year average P/E is 85.5x and the historical range spans 44.2x to 147.8x.

Is APLS stock overvalued or undervalued?

APLS trades at 227.9x P/E, above its 5-year average of 85.5x. The 100th percentile ranking within the 44.2x–147.8x historical range indicates a premium to historical valuation.

Is APLS stock expensive?

Yes, APLS is expensive relative to its own history. The current P/E of 227.9x is above the 5-year average of 85.5x and also above the Healthcare sector median of 22.1x. The stock sits at the 100th percentile of its 5-year valuation range.

What is APLS's historical P/E range?

Over the past 5 years, APLS's P/E ratio has ranged from 44.2x to 147.8x, with a median of 64.7x and an average of 85.5x. The current P/E of 227.9x places the stock at the 100th percentile of this range. Full historical data spans 2025–2026.

How does APLS's P/E compare to the S&P 500?

APLS trades at 227.9x P/E versus the S&P 500 median of 24.3x. The 838% premium to the market typically reflects higher expected earnings growth or quality.

How does APLS's valuation compare to Healthcare peers?

Apellis Pharmaceuticals, Inc. P/E of 227.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is APLS's PEG ratio?

APLS PEG ratio is N/A, based on a P/E of 227.9x and EPS growth of 111.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is APLS's earnings yield?

APLS earnings yield is 0.44%, the inverse of its 227.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

APLS P/E Ratio History (2025–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current44.2x
Period Avg85.5x
Range44.2x - 147.8x
Change-32%
3 quartersSep 30, 2025 - Mar 31, 2026